New Edge Advisors, LLC Gilead Sciences, Inc. Transaction History

New Edge Advisors, LLC

$15 Billion
Q3 2024

A detailed history of New Edge Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 55,996 shares of GILD stock, worth $4.96 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

55,996

Previous 55,118 1.59%

Holding current value

$4.96 Million

Previous $3.78 Million 24.12%

% of portfolio

0.03%

Previous 0.03%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $58,466 - $73,743	878 Added 1.59%	55,996 $4.69 Million
Q2 2024 Aug 15, 2024	SELL	$63.15 - $72.88 $335,137 - $386,774	-5,307 Reduced 8.78%	55,118 $3.78 Million
Q1 2024 May 14, 2024	SELL	$71.58 - $87.29 $74,300 - $90,607	-1,038 Reduced 1.69%	60,425 $4.43 Million
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $163,758 - $185,706	2,235 Added 3.77%	61,463 $4.98 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $277,201 - $302,431	-3,749 Reduced 5.95%	59,228 $4.44 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $1.14 Million - $1.3 Million	15,049 Added 31.4%	62,977 $4.85 Million
Q1 2023 May 12, 2023	BUY	$77.31 - $88.08 $815,929 - $929,596	10,554 Added 28.24%	47,928 $3.98 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $470,640 - $675,677	7,552 Added 25.32%	37,374 $3.21 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $133,786 - $152,818	2,247 Added 8.15%	29,822 $1.84 Million
Q2 2022 Aug 09, 2022	BUY	$57.72 - $65.01 $115,440 - $130,020	2,000 Added 7.82%	27,575 $1.7 Million
Q1 2022 May 13, 2022	SELL	$57.92 - $72.58 $321,571 - $402,964	-5,552 Reduced 17.84%	25,575 $1.52 Million
Q4 2021 Feb 17, 2022	BUY	$64.88 - $73.64 $1.14 Million - $1.29 Million	17,516 Added 128.69%	31,127 $2.26 Million
Q3 2021 Oct 29, 2021	SELL	$67.69 - $73.03 $297,632 - $321,112	-4,397 Reduced 24.42%	13,611 $951,000
Q2 2021 Jul 22, 2021	SELL	$63.47 - $69.35 $89,238 - $97,506	-1,406 Reduced 7.24%	18,008 $1.24 Million
Q1 2021 Apr 26, 2021	SELL	$60.0 - $68.46 $604,620 - $689,871	-10,077 Reduced 34.17%	19,414 $1.26 Million
Q4 2020 Jan 27, 2021	SELL	$56.65 - $64.55 $73,418 - $83,656	-1,296 Reduced 4.21%	29,491 $1.72 Million
Q3 2020 Nov 03, 2020	BUY	$62.1 - $78.08 $226,168 - $284,367	3,642 Added 13.42%	30,787 $1.95 Million
Q2 2020 Jul 29, 2020	SELL	$72.34 - $84.0 $282,777 - $328,356	-3,909 Reduced 12.59%	27,145 $2.09 Million
Q1 2020 May 04, 2020	BUY	$62.63 - $80.22 $1.12 Million - $1.44 Million	17,945 Added 136.89%	31,054 $2.32 Million
Q4 2019 Jan 31, 2020	SELL	$61.62 - $67.78 $41,531 - $45,683	-674 Reduced 4.89%	13,109 $851,000
Q3 2019 Nov 06, 2019	SELL	$62.51 - $69.0 $25,004 - $27,600	-400 Reduced 2.82%	13,783 $874,000
Q2 2019 Aug 05, 2019	BUY	$61.87 - $69.38 $30,378 - $34,065	491 Added 3.59%	14,183 $958,000
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $6.13 Million - $6.87 Million	-98,076 Reduced 87.75%	13,692 $890,000
Q1 2019 May 09, 2019	BUY	$62.53 - $70.05 $6.31 Million - $7.06 Million	100,833 Added 922.11%	111,768 $74,000
Q4 2018 Jan 29, 2019	BUY	$60.54 - $79.0 $219,578 - $286,533	3,627 Added 49.63%	10,935 $684,000
Q3 2018 Oct 29, 2018	SELL	$71.28 - $78.92 $78,764 - $87,206	-1,105 Reduced 13.13%	7,308 $564,000
Q2 2018 Jul 19, 2018	BUY	$64.88 - $75.68 $7,266 - $8,476	112 Added 1.35%	8,413 $600,000
Q1 2018 May 11, 2018	BUY	$72.84 - $88.8 $338,997 - $413,275	4,654 Added 127.61%	8,301 $607,000
Q4 2017 Feb 08, 2018	SELL	$71.15 - $83.52 $49,022 - $57,545	-689 Reduced 15.89%	3,647 $271,000
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $40,453 - $47,948	561 Added 14.86%	4,336 $355,000
Q2 2017 Aug 16, 2017	BUY	N/A	3,775	3,775 $0

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.

Account

New Edge Advisors, LLC Gilead Sciences, Inc. Transaction History